CGenetix: Monitor a transplant with a simple blood test

Hours spent by the patient on an outpatient basis in the hospital, painful procedure, restrictive logistics… the disadvantages of solid biopsy no longer need to be demonstrated. However, in the absence of a viable alternative, it remains the standard technique for monitoring the evolution of a graft. Founded in March 2022, the Parisian start-up CGenetix wants to provide a less invasive solution and is developing a kit to ensure this monitoring using a simple blood test. In this case, detection is done thanks to the epigenetic properties of DNA, more precisely by the identification of methyl groups on circulating DNA, characteristic of organ suffering and cell death. “The analysis can be carried out using classic sequencing and digital PCR technologies. Depending on the number, position and level of methylation, we identify potential cellular destruction very early on,” explains Geoffroy Poulet,…